

Jun 20, 2014

**Notification of approval of the additional indication for chronic pain of
the transdermal long-acting pain relief patch FENTOS[®] TAPE (development code: HFT-290)**

Hisamitsu Pharmaceutical Co., Inc., (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Hirotaka Nakatomi; hereinafter referred to as “Hisamitsu”) announced today that it received approval of the additional indication for chronic pain of the transdermal long-acting pain relief patch FENTOS[®] TAPE (development code: HFT-290; hereinafter referred to as “the product”) for which a supplemental new drug application (NDA) had been made in Japan in July 2013.

Hisamitsu obtained approval for the product in Japan in April 2010 with indication for pain relief in various cancers that accompany moderate to severe pain and has jointly carried out product distribution and activities for the provision and collection of information (1 brand, 2 channels) with Kyowa Hakko Kirin Co., Ltd., (Head office: Chiyoda-ku, Tokyo, Japan; President and CEO: Nobuo Hanai; hereinafter referred to as “Kyowa Hakko Kirin”) since June 2010. To obtain the recent approval, Hisamitsu confirmed the efficacy and safety of the product by conducting a clinical study of once daily administration of the product in patients with moderate to severe chronic pain.

Hisamitsu will continue to market the product jointly with Kyowa Hakko Kirin. Through providing appropriate information of the product, Hisamitsu will contribute to improve quality of life in patients suffering from cancer pain and chronic pain.